PSMA PET/CT对前列腺癌初始分期和根治性放疗计划的影响
研究纳入75例新诊断前列腺癌患者,比较基于常规影像与18F-PSMA PET/CT制定的放疗计划,发现PSMA PET/CT改变了34.7%患者的靶区,并显著提高直肠V60%、股骨最大剂量和肠道最大剂量;分期上调患者的前列腺体积更大。
要点
- PSMA PET/CT使34.7%患者靶区改变,影响根治性放疗计划。
- 基于PSMA的放疗计划直肠V60%更高(19.96% vs 18.1%,P=.024)。
- 分期上调患者前列腺体积更大(77.53±34.76 cc vs 59.76±30.6 cc,P=.026)。
核心结论
- 18F-PSMA PET/CT显著影响前列腺癌分期和放疗计划,导致靶区和剂量学改变,在前列腺体积较大的患者中显著,而在Gleason评分≥8和PSA较高患者中不显著。
研究设计与样本
- 单中心研究纳入2019年1月至2022年12月在本中心接受根治性放疗的75例新诊断前列腺癌患者,每例均行标准影像和18F-PSMA PET/CT,基于两种影像分别制定IMRT或RapidArc放疗计划进行比较。
临床应用与阅片要点
- 作者认为PSMA PET/CT有意义地改变了分期、靶区和剂量学,突显该模态在提高根治性放疗计划准确性方面的价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Comparing risk grouping, target delineation, and dosimetric parameters between RT plans based on conventional imaging (CT and/or MRI pelvis with bone scan) versus 18F-PSMA PET/CT in the same patients.
METHODS: A 75 newly diagnosed PCa patients treated with definitive RT between January 2019 and December 2022 at our center were included. Each underwent standard imaging and 18F-PSMA PET/CT. Two RT plans were generated; one from conventional imaging and another from PSMA PET/CT data using IMRT or RapidArc on the Eclipse (Varian, USA) system. Plans were compared regarding target volumes (TVs), dose-volume histograms (DVH), and doses to organs at risk (OARs).
RESULTS: Mean age was 69.6 ± 8.1 years, and mean pretreatment PSA was 33.47 ± 42.05 ng/mL. Gleason score (GS) was 7 in 50.7% and 8-10 in 26.6%. PSMA-PET/CT altered TVs in 26 patients (34.7%). PSMA-based RT plans showed significantly higher rectal V60% (19.96% vs 18.1%, P = .024), femoral maximum dose (46.37 Gy vs 41.98 Gy, P = .006), and bowel maximum dose (54.7 Gy vs 46.3 Gy, P = .014). Upstaged patients had larger mean prostate volumes (77.53 ± 34.76 cc vs 59.76 ± 30.6 cc; P = .026).
CONCLUSION: 18F-PSMA-PET/CT significantly impacts staging and RT planning in prostate cancer, leading to altered TVs and dosimetry, significantly in patients with larger prostates, but non significantly in patients with GS ≥ 8, and higher PSA levels.
ADVANCES IN KNOWLEDGE: PSMA PET/CT meaningfully changes staging, TVs, and dosimetry. It highlights the modality's value in improving accuracy in definitive RT planning.
引用
- Elsaka R, Hegazy H, Eldrieny A, et al. Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer. Br J Radiol. 2026. PMID: 41808439. doi:10.1093/bjr/tqag057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。